← All trials
NCT02032823
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2014
- Primary completion
- Mar 2, 2020
- Completion date
- Feb 28, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Myrexis Inc.Collaborator
- Harvard UniversityOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Virginia Commonwealth UniversityOverall official - principal investigator
- Tel Aviv UniversityOverall official - principal investigator
- NRG OncologyCollaborator
- Frontier Science & Technology Research Foundation, Inc.Collaborator
- Free University of BrusselsCollaborator
- University of MilanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.